ArticleThe Journal of veterinary medical science2025
Efficacy of tafenoquine in dogs naturally infected with Babesia gibsoni.
Article in The Journal of veterinary medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are various treatments have been reported for canine babesiosis. However, treatment methods that can eliminate the parasites have not been established. The current study aimed to evaluate the therapeutic effects of tafenoquine against natural Babesia gibsoni infection. In total, seven dogs with canine babesiosis and one dog with canine babesiosis not controlled with diminazene aceturate were included. Oral tafenoquine at dose of 10-20 mg/kg was administered orally on days 0 and 7. The hematocrit level and platelet count of the dogs were measured. The clinical symptoms of all dogs rapidly improved. Two dogs relapsed. However, their symptoms improved after two more doses of tafenoquine. Although recurrence could not be prevented, tafenoquine might be a treatment against canine babesiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.